These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24870872)

  • 1. A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):5-6. PubMed ID: 24870872
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
    Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
    Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
    Hu B; Younes A; Westin JR; Turturro F; Claret L; Feng L; Fowler N; Neelapu S; Romaguera J; Hagemeister FB; Rodriguez MA; Samaniego F; Fayad LE; Copeland AR; Nastoupil LJ; Nieto Y; Fanale MA; Oki Y
    Leuk Lymphoma; 2018 Apr; 59(4):863-870. PubMed ID: 28792260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
    Fanale M; Fayad L; Pro B; Samaniego F; Liboon MJ; Nunez C; Horowitz S; Anderlini P; Popat U; Ji Y; Kwak LW; Younes A
    Br J Haematol; 2011 Jul; 154(2):284-6. PubMed ID: 21517809
    [No Abstract]   [Full Text] [Related]  

  • 6. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):7. PubMed ID: 24870873
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
    Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
    Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.
    Budde LE; Zhang MM; Shustov AR; Pagel JM; Gooley TA; Oliveira GR; Chen TL; Knudsen NL; Roden JE; Kammerer BE; Frayo SL; Warr TA; Boyd TE; Press OW; Gopal AK
    Br J Haematol; 2013 Apr; 161(2):183-91. PubMed ID: 23356514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
    Kushner BH; Modak S; Kramer K; Basu EM; Roberts SS; Cheung NK
    Cancer; 2013 Feb; 119(3):665-71. PubMed ID: 22951749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.
    Ribrag V; Nasr F; Bouhris JH; Bosq J; Brault P; Girinsky T; Cosset JM; Munck JN; Corti C; Decaudin D; Pico JL; Hayat M; Carde P
    Bone Marrow Transplant; 1998 May; 21(10):969-74. PubMed ID: 9632268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
    George B; Benson W; Hertzberg MS
    Bone Marrow Transplant; 2012 Jul; 47(7):1001-2. PubMed ID: 22002487
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
    Oki Y; Buglio D; Fanale M; Fayad L; Copeland A; Romaguera J; Kwak LW; Pro B; de Castro Faria S; Neelapu S; Fowler N; Hagemeister F; Zhang J; Zhou S; Feng L; Younes A
    Clin Cancer Res; 2013 Dec; 19(24):6882-90. PubMed ID: 24097867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases].
    Kanamori M; Kumabe T; Saito R; Yamashita Y; Sonoda Y; Tominaga T
    No Shinkei Geka; 2010 Nov; 38(11):997-1005. PubMed ID: 21081811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 2000 Feb; 85(2):217-9. PubMed ID: 10681738
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
    Aurer I; Mitrović Z; Nemet D; Radman I; Sertić D; Serventi-Seiwerth R; Stern-Padovan R; Santek F; Nola M; Mrsić M; Labar B
    J Chemother; 2008 Oct; 20(5):640-4. PubMed ID: 19048695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.